Strata Skin Sciences ( (SSKN) ) just unveiled an announcement.
On March 20, 2025, STRATA Skin Sciences announced the publication of a study highlighting the superior clinical outcomes of their XTRAC® Excimer Laser over other UVB light sources like Excimer Light. The study, conducted by researchers from Nippon Medical School, demonstrated that the excimer laser’s unique technological characteristics, such as deeper penetration and greater activation of melanocyte lineage cells, result in better pigmentation and fewer side effects. This reinforces STRATA’s commitment to providing effective dermatological treatments and underscores their growing presence in Japan, where they have expanded significantly since 2019.
More about Strata Skin Sciences
STRATA Skin Sciences is a medical technology company focused on developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions such as psoriasis, vitiligo, and acne. Their offerings include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System, with a unique Partnership Program in the U.S. that includes a fee per treatment cost structure and comprehensive support services.
YTD Price Performance: -16.35%
Average Trading Volume: 5,318
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.26M
For detailed information about SSKN stock, go to TipRanks’ Stock Analysis page.